Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Teams Up With TB Foundation To Develop New Low-cost Treatment Aimed At Asia, Africa

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Johnson & Johnson plans to work with the Global Alliance for TB Drug Development to speed up the launch of what could be the first drug in decades with a new mechanism to treat tuberculosis
Advertisement

Related Content

J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
J&J Worldwide Chairman Paul Stoffels On Precompetitive Alliances, Patent Pools And Tropical Drugs: An Interview With PharmAsia News
Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report
Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report
The Coartem Story: Novartis Workers In NY Feel Uplift In Battling Malaria
Novartis Looks To New Models For Neglected Disease Research
Novartis Looks To New Models For Neglected Disease Research
Advertisement
UsernamePublicRestriction

Register

SC072001

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel